Jun Xing

Jun Xing is a Senior Director at Sanofi, specializing in Immunology and Global Development Medical Affairs. With experience in overseeing multiple early-phase clinical assets, Jun has contributed to significant studies, including the phase 2b dose selection studies for Clazakizumub and registrational studies for Belatacept. Previously, Jun held positions at Bristol-Myers Squibb as a Principal Biostatistician and Senior Associate Director, among others. Currently pursuing a Ph.D. in Biostatistics at the University of California, Los Angeles, Jun also holds a B.S. in Biophysics from Fudan University and an M.S. in Biochemistry from the University of California, Riverside.